Previous 10 | Next 10 |
Back in May, Agile Therapeutics ( AGRX ), publicized that they resubmitted Twirla’s NDA to FDA. Twirla is Agile’s lead product candidate that is a low-dose combination hormonal contraceptive patch. Subsequently, Agile stated that the FDA accepted the NDA resubmission with t...
PRINCETON, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,...
Glu Mobile (NASDAQ: GLUU ) -29% on Q2 earnings . More news on: Glu Mobile Inc., Obalon Therapeutics, Inc., Workhorse Group Inc., Stocks on the move, Read more ...
PRINCETON, N.J., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 12,631,579 shares of its common stock at a public offering price of $0.95 per share. The gross ...
PRINCETON, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile ...
Agile Therapeutics (NASDAQ: AGRX ): Q2 GAAP EPS of -$0.08 beats by $0.04 . More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
FDA Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 Cash Expected to Enable Company to Fund Operations through the End of 2019 PRINCETON, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare compan...
Agile Therapeutics ( AGRX +0.8% ) announced the appointment of Dennis P. Reilly as Chief Financial Officer effective August 5, 2019. More news on: Agile Therapeutics, Inc., Read more ...
Dennis P. Reilly to bring commercial experience to management team Appointment Effective August 5, 2019 PRINCETON, N.J., July 18, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Dennis P. Reil...
Back in May, Agile Therapeutics ( AGRX ), revealed that they resubmitted their NDA for its primary product candidate, Twirla, a low-dose combination hormonal contraceptive patch. Shortly after, Agile announced that the FDA accepted Twirla's NDA resubmission with the PDUFA date set for No...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...